Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Oliveira, Marcela Brito ^a   Calixto, Giovana ^a   Graminha, Márcia ^a   Cerecetto, Hugo ^b   González, Mercedes ^b   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; EMULSION;

ANIMAL CELL; ARTICLE; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; IN VITRO STUDY; MACROPHAGE; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE; SHEAR RATE; SHEAR STRESS; SKIN LEISHMANIASIS; TOPICAL TREATMENT; X RAY DIFFRACTION; ZETA POTENTIAL; ADHESION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECTS; EMULSION; FLOW KINETICS; HARDNESS; HUMAN; LEISHMANIASIS, CUTANEOUS; PHASE TRANSITION; PIG; STATIC ELECTRICITY; TOPICAL DRUG ADMINISTRATION;

ADHESIVENESS; ADMINISTRATION, TOPICAL; ANIMALS; CELL LINE; EMULSIONS; FEMALE; FLUCONAZOLE; HARDNESS; HUMANS; IN VITRO TECHNIQUES; LEISHMANIASIS, CUTANEOUS; MICE, INBRED BALB C; PARTICLE SIZE; PHASE TRANSITION; RHEOLOGY; STATIC ELECTRICITY; SUS SCROFA; X-RAY DIFFRACTION;

EID: 84947648625     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/396894     Document Type: Article

References (64)

1. J. Alvar, I.D. Vélez, C. Bernet al., "Leishmaniasisworldwide and global estimates of its incidence," PLoS ONE, vol. 7, no. 5, Article ID e35671, 2012.
2. S. R. Reis, L. H. M. Gomes, N. M. Ferreira et al., "Ocorrência de flebotomíneos (Diptera: Psychodidae: Phlebotominae) no ambiente peridomiciliar em área de foco de transmissão de leishmaniose tegumentar nomunićipio deManaus, Amazonas," Acta Amazonica, vol. 43, no. 1, pp. 121-123, 2013.
3. P. Desjeux, "Leishmaniasis: current situation and new perspectives," Comparative Immunology, Microbiology & Infectious Diseases, vol. 27, no. 5, pp. 305-318, 2004.
4. J. Alvar, I. D. Vélez, C. Bern et al., "Leishmaniasis worldwide and global estimates of its incidence," PLoS ONE, vol. 7, no. 5, Article ID e35671, 2012.
5. J. J. Shaw and R. Lainson, "Leishmaniasis in Brazil: X. Some observations on intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 69, no. 3, pp. 323-335, 1975.
6. B. Chawla and R. Madhubala, "Drug targets in Leishmania," Journal of Parasitic Diseases, vol. 34, no. 1, pp. 1-13, 2010.
7. J. Faergemann and H. Laufen, "Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat," Clinical and Experimental Dermatology, vol. 18, no. 2, pp. 102-106, 1993.
8. S. R. C. J. Santos, E. V. Campos, C. Sanches, D. S. Gomez, and M. C. Ferreira, "Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients," Clinics, vol. 65, no. 2, pp. 237-243, 2010.
9. K. W. Brammer, P. R. Farrow, and J. K. Faulkner, "Pharmacokinetics and tissue penetration of fluconazole in humans," Reviews of Infectious Diseases, vol. 12, supplement 3, pp. S318-S326, 1990.
10. K. Turner, P. Manzoni, D.K. Benjamin, M. Cohen-Wolkowiez, P.B. Smith, and M. M. Laughon, "Fluconazole pharmacokinetics and safety in premature infants," Current Medicinal Chemistry, vol. 19, no. 27, pp. 4617-4620, 2012.
11. M. Rahman, M. A. Wahab, and M. S. I. Khan, "Efficacy of pulse therapy of oral fluconazole in the treatment of seborrheic dermatitis," Journal of Dhaka National Medical College & Hospital, vol. 17, no. 2, pp. 25-29, 2012.
12. A. C. Ayub, A. D. M. Gomes, M. V. C. Lima, C. D. Vianna- Soares, and L. A. M. Ferreira, "Topical delivery of fluconazole: in vitro skin penetration and permeation using emulsions as dosage forms," Drug Development and Industrial Pharmacy, vol.33, no. 3, pp. 273-280, 2007.
13. C. Salerno, A.M. Carlucci, and C. Bregni, "Study of in vitro drug release and percutaneous absorption of fluconazole fromtopical dosage forms," AAPS PharmSciTech, vol. 11, no. 2, pp. 986-993, 2010.
14. E. B.D. Lima, C. Porto, J. O. C. D. Motta, and R.N. R. Sampaio, "Tratamento da leishmaniose tegumentar Americana," Anais Brasileiros De Dermatologia, vol. 82, no. 2, pp. 111-124, 2007.
15. F. E. D. Silva, C. Ziech, G. D. Pavoni, and R. Pasquali, "Desenvolvimento de comprimidos contendo fluconazol por compress ão direta," Latin American Journal of Pharmacy, vol. 28, no.4, pp. 604-608, 2009.
16. P. Minodier and P. Parola, "Cutaneous leishmaniasis treatment," TravelMedicine and Infectious Disease, vol. 5, no. 3, pp. 150-158, 2007.
17. N. Shakya, P. Bajpai, and S. Gupta, "Therapeutic switching in Leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs," Journal of Parasitic Diseases, vol. 35, no.2, pp. 104-112, 2011.
18. A. A. Alrajhi, E. A. Ibrahim, E. B. De Vol, M. Khairat, R. M. Faris, and J.H. Maguire, "Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major," The New England Journal of Medicine, vol. 346, no. 12, pp. 891-895, 2002.
19. S.V. Mussi, A.P. Fernandes, and L. A.M. Ferreira, "Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis," Parasitology Research, vol. 100, no. 6, pp. 1221-1226, 2007.
20. F. K. dos Santos, M. H. Oyafuso, C. P. Kiill, M. P. Daflon- Gremião, and M. Chorilli, "Nanotechnology-based drug delivery systems for treatment of hyperproliferative skin diseases-a review," Current Nanoscience, vol. 9, no. 1, pp. 159-167, 2013.
21. T. P. Formariz, M. C. C. Urban, A. Silva Junior et al., "Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos," Revista Brasileira de Ciências Farmacêuticas, vol.41, no. 3, pp. 301-313, 2005.
22. R. L. Shinde, A. B. Jindal, and P. V. Devarajan, "Microemulsions and nanoemulsions for targeted drug delivery to the brain," Current Nanoscience, vol. 7, no. 1, pp. 119-133, 2011.
23. A. C. Sintov and L. Shapiro, "New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo," Journal of Controlled Release, vol.95, no. 2, pp. 173-183, 2004.
24. T. P. Formariz, L. A. Chiavacci, M. V. Scarpa et al., "Structure and viscoelastic behavior of pharmaceutical biocompatible anionic microemulsions containing the antitumoral drug compound doxorubicin," Colloids and Surfaces B: Biointerfaces, vol.77, no. 1, pp. 47-53, 2010.
25. G. M. El Maghraby, "Microemulsions as transdermal drug delivery systems," Current Nanoscience, vol. 8, no. 4, pp. 504-511, 2012.
26. A. Oliveira and M. Scarpa, "Microemulsões I: fundamentos teóricos da formação do sistema microemulsionado," Infarma, vol. 13, pp. 73-79, 2001.
27. A. S. Cunha Júnior, S. L. Fialho, L. B. Carneiro, and F. Oréfice, "Microemulsões como veículo de drogas para administração ocular tópica," Arquivos Brasileiros de Oftalmologia, vol. 66, no.3, pp. 385-391, 2003.
28. V. A. F. F. M. dos Santos, K. M. Leite, M. da Costa Siqueira et al., "Antiprotozoal activity of quinonemethide triterpenes from Maytenus ilicifolia (Celastraceae)," Molecules, vol. 18, no.1, pp. 1053-1062, 2013.
29. J. Soto, P. Fuya, R. Herrera, and J. Berman, "Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment forAmerican cutaneous leishmaniasis: Controlled study," Clinical Infectious Diseases, vol. 26, no.1, pp. 56-58, 1998.
30. P. Mura, M. Bragagni, N. Mennini, M. Cirri, and F. Maestrelli, "Development of liposomal and microemulsion formulations for transdermal delivery of clonazepam: effect of randomly methylated β-cyclodextrin," International Journal of Pharmaceutics, vol. 475, no. 1-2, pp. 306-314, 2014.
31. K. Karim, A. Mandal, N. Biswas et al., "Niosome: a future of targeted drug delivery systems," Journal of Advanced Pharmaceutical Technology and Research, vol. 1, no. 4, pp. 374-380, 2010.
32. T. P. Formariz, L. A. Chiavacci, V. H. V. Sarmento, C. V. Santilli, E. S. Tabosa do Egito, and A. G. Oliveira, "Relationship between structural features and in vitro release of doxorubicin from biocompatible anionic microemulsion," Colloids and Surfaces B: Biointerfaces, vol. 60, no. 1, pp. 28-35, 2007.
33. P. S. Prestes, M. Chorilli, L. A. Chiavacci, M. V. Scarpa, and G.R. Leonardi, "Physicochemical characterization and rheological behavior evaluation of the liquid crystalline mesophases developed with different silicones," Journal of Dispersion Science and Technology, vol. 31, no. 1, pp. 117-123, 2009.
34. J. A. D. Silva, D. P. D. Santana, D. G. C. Bedor et al., "Estudo de liberação e permeação in vitro do diclofenaco de dietilamônio em microemulsão gel-like," Química Nova, vol. 32, no. 6, pp.1389-1393, 2009.
35. R. Pouliot, L. Germain, F. A. Auger, N. Tremblay, and J. Juhasz, "Physical characterization of the stratumcorneum of an in vitro human skin equivalent produced by tissue engineering and its comparison with normal human skin by ATR-FTIR spectroscopy and thermal analysis (DSC)," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1439, no. 3, pp.341-352, 1999.
36. G. Calixto, A. C. Yoshii, H. Rocha e Silva et al., "Polyacrylic acid polymers hydrogels intended to topical drug delivery: preparation and characterization," Pharmaceutical Development and Technology, pp. 1-7, 2014.
37. F. C. Carvalho, G. Calixto, I. N. Hatakeyama, G.M. Luz, M. P.D. Gremião, and M. Chorilli, "Rheological, mechanical, and bioadhesive behavior of hydrogels to optimize skin delivery systems," Drug Development and Industrial Pharmacy, vol. 39, no. 11, pp. 1750-1757, 2013.
38. M. Jumaa, P. Kleinebudde, and B.W. Müller, "Physicochemical properties and hemolytic effect of different lipid emulsion formulations using a mixture of emulsifiers," Pharmaceutica Acta Helvetiae, vol. 73, no. 6, pp. 293-301, 1999.
39. Z.-R. Huang, "Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion," Acta Pharmacologica Sinica, vol. 29, no. 9, pp. 1094-1102, 2008.
40. S. Muelas-Serrano, J. J. Nogal, R. A. Martínez-Díaz, J. A. Escario, A. R. Martínez-Fernández, and A. Gómez-Barrio, "In vitro screening ofAmerican plant extracts on Trypanosoma cruzi and Trichomonas vaginalis," Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 101-107, 2000.
41. G. P. Kumar and P. Rajeshwarrao, "Nonionic surfactant vesicular systems for effective drug delivery-an overview," Acta Pharmaceutica Sinica B, vol. 1, no. 4, pp. 208-219, 2011.
42. R. Rajera, K. Nagpal, S.K. Singh, and D. N. Mishra, "Niosomes: a controlled and novel drug delivery system," Biological and Pharmaceutical Bulletin, vol. 34, no. 7, pp. 945-953, 2011.
43. N. B. Mahale, P. D. Thakkar, R. G. Mali, D. R. Walunj, and S. R. Chaudhari, "Niosomes: novel sustained release nonionic stable vesicular systems-an overview," Advances in Colloid and Interface Science, vol. 183-184, pp. 46-54, 2012.
44. A. Sankhyan and P. Pawar, "Recent trends in niosome as vesicular drug delivery system," Journal of Applied Pharmaceutical Science, vol. 2, no. 6, pp. 20-32, 2012.
45. U. Goyal, R. Arora, and G. Aggarwal, "Formulation design and evaluation of a self-microemulsifying drug delivery system of lovastatin," Acta Pharmaceutica, vol. 62, no. 3, pp. 357-370, 2012.
46. G. B. R. F. da Silva, M.V. Scarpa, G. Rossanezi, E. S. T. do Egito, and A. G. de Oliveira, "Development and characterization of biocompatible isotropic and anisotropic oil-in-water colloidal dispersions as a new delivery system for methyl dihydrojasmonate antitumor drug," International Journal of Nanomedicine, vol. 9, no. 1, pp. 867-876, 2014.
47. M. Mosca, A. Ceglie, and L. Ambrosone, "Effect of membrane composition on lipid oxidation in liposomes," Chemistry and Physics of Lipids, vol. 164, no. 2, pp. 158-165, 2011.
48. W. L. Lindner, "Characterization of the crystalline, intermediate and amorphous phase in poly(ethylene terephthalate) fibres by X-ray diffraction," Polymer, vol. 14, no. 1, pp. 9-15, 1973.
49. S. V. Canevarolo Jr., Técnicas de caracterização de polímeros, Artliber, São Paulo, Brazil, 2004.
50. E. Ziémons, H. Bourichi, J. Mantanus et al., "Determination of binary polymorphic mixtures of fluconazole using near infrared spectroscopy and X-ray powder diffraction: a comparative study based on the pre-validation stage results," Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 5, pp. 1208-1212, 2011.
51. A. S. Can, M. S. Erdal, S. Güngör, and Y. Özsoy, "Optimization and characterization of chitosan films for transdermal delivery of ondansetron," Molecules, vol. 18, no. 5, pp. 5455-5471, 2013.
52. D. S. Jones, A. D. Woolfson, A. F. Brown, and M. J. O'Neill, "Mucoadhesive, syringeable drug delivery systems for controlled application of metronidazole to the periodontal pocket: in vitro release kinetics, syringeability, mechanical andmucoadhesive properties," Journal of Controlled Release, vol. 49, no. 1, pp. 71-79, 1997.
53. Y. G. Bachhav and V. B. Patravale, "Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation," International Journal of Pharmaceutics, vol. 365, no. 1-2, pp. 175-179, 2009.
54. S. V. P. Malheiros, N. C. Meirelles, and E. de Paula, "Pathways involved in trifluoperazine-, dibucaine- and praziquantelinduced hemolysis," Biophysical Chemistry, vol. 83, no. 2, pp.89-100, 2000.
55. R. Abbasalipourkabir, A. Salehzadeh, and R. Abdullah, "Cytotoxicity effect of solid lipid nanoparticles on human breast cancer cell lines," Biotechnology, vol. 10, no. 6, pp. 528-533, 2011.
56. A. C. Silva, D. Santos, D. C. Ferreira, and E. B. Souto, "Minoxidil- loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations," Pharmazie, vol. 64, no. 3, pp. 177-182, 2009.
57. M.M. Bastos, N. Boechat, A. T. Gomes et al., "OUso de Porfirinas em Terapia Fotodinâmica no Tratamento da Leishmaniose Cutânea," Revista Virtual de Química, vol. 4, no. 3, pp. 257-267, 2012.
58. A. Weingärtner, G. Kemmer, F. D. Müller et al., "Leishmania promastigotes lack phosphatidylserine but bind annexin V upon permeabilization or miltefosine treatment," PLoS ONE, vol. 7, no. 8, Article ID e42070, 2012.
59. A. Ponte-Sucre, J. H. Faber, T. Guider et al., "Activities of naphthylisoquinoline alkaloids and synthetic analogs against Lishmania major," Antimicrobial Agents and Chemotherapy, vol. 51, no. 1, pp. 188-194, 2007.
60. J. L. Siqueira-Neto, O.-R. Song, H. Oh et al., "Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds," PLoS Neglected Tropical Diseases, vol. 4, no. 5, article e675, 2010.
61. G. Bringmann, K. Thomale, S. Bischof et al., "A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts," Antimicrobial Agents and Chemotherapy, vol. 57, no. 7, pp. 3003-3011, 2013.
62. S. Magdum Chandrakant, S. Naikwade Nilofar, and R. Shah Rohit, "Preparation and evaluation of fluconazole topical microemulsion," Journal of Pharmacy Research, vol. 2, no. 3, pp.557-562, 2009.
63. T. P. Formariz, V. H. V. Sarmento, A. A. Silva-Junior, M. V. Scarpa, C. V. Santilli, and A. G. Oliveira, "Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine," Colloids and Surfaces B: Biointerfaces, vol. 51, no. 1, pp. 54-61, 2006.
64. C. H. Lee, V. Moturi, and Y. Lee, "Thixotropic property in pharmaceutical formulations," Journal of Controlled Release, vol. 136, no. 2, pp. 88-98, 2009.